What is Kalaris Therapeutics, Inc.'s earnings per share (EPS)?

Kalaris Therapeutics, Inc. (KLRS) reported diluted earnings per share of -$2.85 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kalaris Therapeutics, Inc. (KLRS) Financials

KLRS

FY2025 annual

Net Income -$43.4M YoY not available

EPS (Diluted) -$2.85 YoY not available

Free Cash Flow -$38.6M YoY not available

Operating Cash Flow -$38.4M -85.6% YoY

Market Cap $75.7M as of Sep 16, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.3x on $57.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KLRS SEC filings page.

This page shows Kalaris Therapeutics, Inc. (KLRS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KLRS FY2025 2026-08-29

Financing now supports a smaller development program while liquidity has been rebuilt after years of heavy operating cash use.

The business became less cash-intensive in FY2025: operating cash flow was -$38.4M versus -$124.5M in FY2023, indicating reduced spending pressure rather than internally funded operations. R&D was $30.8M in FY2025 versus $133.1M in FY2023, so the improvement reflects a smaller development footprint more than commercial cash generation.

FY2025 financing cash flow of $155.0M greatly exceeded operating cash flow of -$38.4M, showing that balance-sheet capacity was rebuilt mainly through financing activity rather than business-generated cash. The reported liquidity measure of 36.9 months of annual operating outflow captures that strengthened funding position at year-end.

The short-term balance-sheet position shifted sharply: the current ratio moved from 0.1x in FY2024 to 12.2x in FY2025, indicating restored current-asset coverage after acute tightness. Positive equity of $78.8M in FY2025 contrasts with negative equity of -$45.0M in FY2023, making capital structure—not margins—the clearest measure of the recent reset.

Financial Health Signals

Financial health score not available

Kalaris Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/5

Kalaris Therapeutics, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Kalaris Therapeutics, Inc. reported a net loss of $43.4M while operations used $38.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Kalaris Therapeutics, Inc. reported an operating loss of $46.2M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$12.4M

QoQ-4.7%

Kalaris Therapeutics, Inc.'s EBITDA was -$12.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is down 4.7%.

Net Income

-$11.5M

YoY-1.5%

QoQ-6.1%

Kalaris Therapeutics, Inc. reported -$11.5M in net income in Q2 2026. This represents a decrease of 1.5% from the same quarter a year earlier. Against the prior quarter it is down 6.1%.

EPS (Diluted)

-$0.48

YoY+21.3%

QoQ-4.3%

Kalaris Therapeutics, Inc. earned -$0.48 per diluted share (EPS) in Q2 2026. This represents an increase of 21.3% from the same quarter a year earlier. Against the prior quarter it is down 4.3%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$43.2M

YoY-51.2%

QoQ+25.4%

5Y CAGR-28.1%

Kalaris Therapeutics, Inc. held $43.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

24M

YoY+27.3%

QoQ+0.1%

5Y CAGR-18.2%

Kalaris Therapeutics, Inc. had 24M shares outstanding in Q2 2026. This represents an increase of 27.3% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-20.0%

YoY+1.4pp

QoQ-4.1pp

Kalaris Therapeutics, Inc.'s ROE was -20.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$9.0M

YoY+6.8%

QoQ+19.1%

Kalaris Therapeutics, Inc. invested $9.0M in research and development in Q2 2026. This represents an increase of 6.8% from the same quarter a year earlier. Against the prior quarter it is up 19.1%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

KLRS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KLRS quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$165K
R&D Expenses	N/A	$30.8M	N/A	$133.1M+11.9%	$118.9M-1.5%	$120.7M+143.1%	$49.7M+205.7%	$16.2M
SG&A Expenses	N/A	$15.4M+130.2%	$6.7M-86.1%	$48.3M-7.8%	$52.3M+6.6%	$49.1M+126.8%	$21.6M+103.9%	$10.6M
Operating Income	N/A	-$46.2M	N/A	-$199.9M-16.8%	-$171.2M-0.8%	-$169.8M-138.1%	-$71.3M-167.1%	-$26.7M
EBITDA	N/A	-$46.1M	N/A	-$199.5M-17.0%	-$170.5M-0.5%	-$169.6M-138.1%	-$71.2M-167.0%	-$26.7M
Interest Expense	N/A	$1.4M-46.6%	$2.7M	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0+100.0%	-$126K+52.5%	-$265K-126.3%	$1.0M	N/A	N/A
Net Income	N/A	-$43.4M	N/A	-$190.4M-12.9%	-$168.7M+1.9%	-$172.0M-146.4%	-$69.8M-192.7%	-$23.8M
EPS (Basic)	N/A	-$2.85+94.5%	-$51.77-23.0%	-$42.09-1813.2%	-$2.20+19.7%	-$2.74	N/A	N/A
EPS (Diluted)	-$2.02	-$2.85	-$51.77	-$42.09	-$2.20+19.7%	-$2.74	N/A	N/A
Diluted Shares (Avg)	N/A	15M	1M	5M	77M+22.1%	63M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$9.0M+6.8%	$7.6M+25.6%	N/A	$9.1M-74.7%	$8.4M+162.8%	$6.0M+207.5%	N/A	$36.0M+5.5%
SG&A Expenses	$3.4M-11.7%	$4.3M-1.5%	N/A	$3.6M+97.6%	$3.8M+291.0%	$4.3M+618.3%	N/A	$1.8M-85.7%
Operating Income	-$12.4M-1.1%	-$11.8M-14.3%	N/A	-$12.7M+66.3%	-$12.3M-192.7%	-$10.4M-304.0%	N/A	-$37.8M+19.4%
EBITDA	-$12.4M	-$11.8M	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$0	$0-100.0%	N/A	$0-100.0%	$0-100.0%	$1.4M+1750.0%	N/A	$815K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$11.5M-1.5%	-$10.9M-6.5%	N/A	-$11.9M+68.8%	-$11.3M-100.9%	-$10.2M-199.3%	N/A	-$38.1M+14.0%
EPS (Basic)	-$0.48+21.3%	-$0.46+81.7%	-$0.44+96.1%	-$0.64+97.7%	-$0.61+85.7%	-$2.52+3.1%	-$11.38+72.1%	-$28.16-7120.5%
EPS (Diluted)	-$0.48+21.3%	-$0.46	-$0.44	-$0.64	-$0.61	-$2.52	-$11.38	-$28.16
Diluted Shares (Avg)	24M+27.2%	24M	N/A	19M	19M	4M	N/A	1M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

KLRS Balance Sheet

KLRS quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Total Assets	$121.7M+1875.6%	$6.2M-96.8%	$190.8M-31.1%	$277.1M-3.3%	$286.6M-22.7%	$370.8M+166.0%	$139.4M
Current Assets	$118.8M+4459.1%	$2.6M-98.6%	$187.6M-22.8%	$243.1M-4.1%	$253.3M-29.9%	$361.3M+183.8%	$127.3M
Cash & Equivalents	$98.1M+5882.6%	$1.6M-98.2%	$90.1M-15.1%	$106.1M-47.4%	$201.7M+64.4%	$122.7M+100.8%	$61.1M
Short-Term Investments	$19.9M	$0-100.0%	$93.8M-26.5%	$127.7M+174.9%	$46.5M-80.1%	$233.7M+259.5%	$65.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$42.9M-58.2%	$102.8M-56.4%	$235.8M+348.7%	$52.6M-14.3%	$61.3M+245.4%	$17.8M-90.7%	$190.9M
Current Liabilities	$9.7M-60.7%	$24.7M-12.9%	$28.4M+16.6%	$24.3M-35.7%	$37.9M+207.9%	$12.3M+35.0%	$9.1M
Non-Current Liabilities	$33.2M-57.5%	$78.1M-62.4%	$207.4M+635.1%	$28.2M+20.2%	$23.5M+329.7%	$5.5M-97.0%	$181.8M
Total Equity	$78.8M+181.6%	-$96.6M-114.6%	-$45.0M-120.1%	$224.5M-0.3%	$225.3M-36.2%	$353.1M+785.5%	-$51.5M
Retained Earnings	-$160.0M-37.3%	-$116.6M+82.2%	-$656.2M-40.9%	-$465.8M-56.8%	-$297.1M-137.5%	-$125.1M-126.1%	-$55.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$99.5M+7.2%	$109.8M+6.5%	$121.7M+1875.6%	$81.2M-33.8%	$92.8M-29.1%	$103.1M-28.5%	$6.2M-96.8%	$122.5M-50.7%
Current Assets	$95.9M+4.7%	$98.5M-3.6%	$118.8M+4459.1%	$78.2M-36.2%	$91.7M-29.5%	$102.2M-27.8%	$2.6M-98.6%	$122.5M-44.3%
Cash & Equivalents	$43.2M-51.2%	$34.4M-65.9%	$98.1M+5882.6%	$42.4M+2115.7%	$88.4M+1317.3%	$101.0M+1831.6%	$1.6M-98.2%	$1.9M-98.0%
Short-Term Investments	$50.4M	$62.8M	$19.9M	$34.6M+592.9%	$0-100.0%	$0-100.0%	$0-100.0%	$5.0M-95.8%
Long-Term Investments	$0	$7.7M	$0	$0	$0	$0	$0	$0
Total Liabilities	$41.9M+5.4%	$41.2M+5.2%	$42.9M-58.2%	$39.3M-81.4%	$39.7M-78.2%	$39.2M-79.5%	$102.8M-56.4%	$211.9M+300.0%
Current Liabilities	$8.7M+14.2%	$8.1M+13.1%	$9.7M-60.7%	$6.1M+329.5%	$7.7M+224.3%	$7.1M-6.7%	$24.7M-12.9%	$1.4M-95.7%
Non-Current Liabilities	$33.1M+3.3%	$33.2M+3.4%	$33.2M-57.5%	$33.2M-84.2%	$32.1M-82.2%	$32.1M-82.6%	$78.1M-62.4%	$210.5M+957.1%
Total Equity	$57.7M+8.6%	$68.6M+7.3%	$78.8M+181.6%	$41.9M+146.8%	$53.1M+203.1%	$63.9M+234.4%	-$96.6M-114.6%	-$89.4M-145.8%
Retained Earnings	-$182.4M-32.0%	-$170.9M-34.8%	-$160.0M-37.3%	-$150.0M+78.5%	-$138.1M+80.1%	-$126.8M+81.5%	-$116.6M+82.2%	-$696.7M-16.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

KLRS Cash Flow Statement

KLRS quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Cash Flow	-$41.0M	-$38.4M-85.6%	-$20.7M+83.4%	-$124.5M+12.4%	-$142.1M-33.6%	-$106.3M-74.8%	-$60.8M-201.7%	-$20.2M
Depreciation & Amortization	N/A	$13K	N/A	$398K-45.0%	$723K+282.5%	$189K+158.9%	$73K+284.2%	$19K
Stock-Based Compensation	N/A	$1.9M+116.3%	$895K-97.8%	$40.8M-1.3%	$41.3M-6.0%	$44.0M+366.4%	$9.4M+226.3%	$2.9M
Capital Expenditures	N/A	$200K	N/A	N/A	N/A	$26K-88.9%	$235K-30.7%	$339K
Free Cash Flow	N/A	-$38.6M	N/A	N/A	N/A	-$106.3M-74.2%	-$61.0M-197.9%	-$20.5M
Investing Cash Flow	N/A	-$19.7M	N/A	$38.0M+147.2%	-$80.5M-143.3%	$186.0M+209.7%	-$169.5M-162.2%	-$64.6M
Financing Cash Flow	$45.7M	$155.0M+709.9%	$19.1M-72.8%	$70.5M-44.5%	$127.0M+54624.6%	$232K-99.9%	$292.0M+141.5%	$120.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$11.0M+11.9%	-$11.6M-55.6%	-$7.1M+10.1%	-$11.3M-161.9%	-$12.5M-215.8%	-$7.4M-64.6%	-$7.9M+74.5%	-$4.3M+87.4%
Depreciation & Amortization	$10K	$10K	$10K	N/A	N/A	N/A	N/A	N/A
Stock-Based Compensation	$644K+9.0%	$580K+55.1%	N/A	$638K+143.5%	$591K+83.5%	$374K+1106.5%	N/A	$262K-97.5%
Capital Expenditures	N/A	N/A	$17K	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	-$7.1M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$20.2M	-$50.4M	$15.0M+199.7%	N/A	N/A	N/A	$5.0M-80.2%	$20.0M+129.9%
Financing Cash Flow	-$377K	-$1.7M-101.6%	$47.7M+530.1%	$0-100.0%	$0-100.0%	$107.3M+1530.4%	$7.6M+68781.8%	$1K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KLRS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KLRS quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-16182.4%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-14447.9%
Return on Equity	-55.1%	N/A	N/A	-75.1%+1.2pp	-76.3%-56.6pp	-19.8%	N/A
Return on Assets	-35.7%	N/A	-99.8%-38.9pp	-60.9%-0.9pp	-60.0%-41.2pp	-18.8%-1.7pp	-17.1%
Current Ratio	12.23+12.1x	0.11-6.5x	6.61-3.4x	9.99+3.3x	6.69-22.7x	29.39+15.4x	13.98
Debt-to-Equity	0.54	N/A	N/A	0.230.0x	0.27+0.2x	0.05	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-12420.6%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-20.0%+1.4pp	-15.8%+0.1pp	N/A	-28.4%	-21.4%	-16.0%	N/A	N/A
Return on Assets	-11.6%+0.7pp	-9.9%0.0pp	N/A	-14.6%+16.4pp	-12.2%-7.9pp	-9.9%-7.5pp	N/A	-31.1%-13.3pp
Current Ratio	10.98-1.0x	12.19-2.1x	12.23+12.1x	12.89-73.9x	11.98-43.1x	14.31-4.2x	0.11-6.5x	86.78+80.1x
Debt-to-Equity	0.730.0x	0.600.0x	0.54	0.94	0.75	0.61	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Kalaris Therapeutics, Inc. KLRS	FY2025	N/A	-$43.4M	N/A	$75.7M	—
Acumen Pharmaceuticals, Inc. ABOS	FY2025	N/A	-$121.3M	N/A	$209.0M	—
Immunic, Inc. IMUX	FY2025	N/A	-$97.2M	N/A	$141.5M	—
Nutriband Inc. NTRB	FY2026	$2.0M	-$8.2M	N/A	$82.9M	50/100
ANEBULO PHARMAC INC ANEB	FY2025	N/A	-$8.5M	N/A	$14.7M	—
Sutro Biopharma, Inc. STRO	FY2025	$102.5M	-$191.0M	N/A	$274.6M	48/100

Where Kalaris Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Kalaris Therapeutics, Inc. profitable?

No, Kalaris Therapeutics, Inc. (KLRS) reported a net income of -$43.4M in fiscal year 2025.

What is Kalaris Therapeutics, Inc.'s EBITDA?

Kalaris Therapeutics, Inc. (KLRS) had EBITDA of -$46.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kalaris Therapeutics, Inc.'s return on equity (ROE)?

Kalaris Therapeutics, Inc. (KLRS) has a return on equity of -55.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Kalaris Therapeutics, Inc.'s free cash flow?

Kalaris Therapeutics, Inc. (KLRS) recorded an outflow of $38.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kalaris Therapeutics, Inc.'s operating cash flow?

Kalaris Therapeutics, Inc. (KLRS) recorded an outflow of $38.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Kalaris Therapeutics, Inc.'s total assets?

Kalaris Therapeutics, Inc. (KLRS) had $121.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kalaris Therapeutics, Inc.'s capital expenditures?

Kalaris Therapeutics, Inc. (KLRS) invested $200K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kalaris Therapeutics, Inc. spend on research and development?

Kalaris Therapeutics, Inc. (KLRS) invested $30.8M in research and development during fiscal year 2025.

How many shares does Kalaris Therapeutics, Inc. have outstanding?

Kalaris Therapeutics, Inc. (KLRS) had 23M shares outstanding as of fiscal year 2025.

What is Kalaris Therapeutics, Inc.'s current ratio?

Kalaris Therapeutics, Inc. (KLRS) had a current ratio of 12.23 as of fiscal year 2025, which is generally considered healthy.

What is Kalaris Therapeutics, Inc.'s debt-to-equity ratio?

Kalaris Therapeutics, Inc. (KLRS) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kalaris Therapeutics, Inc.'s return on assets (ROA)?

Kalaris Therapeutics, Inc. (KLRS) had a return on assets of -35.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Kalaris Therapeutics, Inc.'s P/E ratio?

Kalaris Therapeutics, Inc. (KLRS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $75.7M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Kalaris Therapeutics, Inc.'s price-to-sales ratio?

Kalaris Therapeutics, Inc. (KLRS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $75.7M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Kalaris Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Kalaris Therapeutics, Inc. (KLRS) held $118.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $38.4M over that year. Dividing the one by the other, the reported balance equals about 37 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Kalaris Therapeutics, Inc.'s Piotroski F-Score?

Kalaris Therapeutics, Inc. (KLRS) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kalaris Therapeutics, Inc.'s earnings high quality?

Kalaris Therapeutics, Inc. (KLRS) reported a net loss of $43.4M while operations used $38.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kalaris Therapeutics, Inc. cover its interest payments?

Kalaris Therapeutics, Inc. (KLRS) reported an operating loss of $46.2M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.